202 related articles for article (PubMed ID: 37999872)
21. Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.
Stauder R; Lambert J; Desruol-Allardin S; Savre I; Gaugler L; Stojkov I; Siebert U; Chevrou-Séverac H
Eur J Haematol; 2020 May; 104(5):476-487. PubMed ID: 31985078
[TBL] [Abstract][Full Text] [Related]
22. [Current state of treatment for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2023; 64(9):988-997. PubMed ID: 37793875
[TBL] [Abstract][Full Text] [Related]
23. MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.
Guo Y; Strickland SA; Mohan S; Li S; Bosompem A; Vickers KC; Zhao S; Sheng Q; Kim AS
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28084850
[TBL] [Abstract][Full Text] [Related]
24. Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes.
Kwon A; Weinberg OK
Clin Lab Med; 2023 Dec; 43(4):657-667. PubMed ID: 37865509
[TBL] [Abstract][Full Text] [Related]
25. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
Yokoyama K; Shimizu E; Yokoyama N; Nakamura S; Kasajima R; Ogawa M; Takei T; Ito M; Kobayashi A; Yamaguchi R; Imoto S; Miyano S; Tojo A
Blood Adv; 2018 Oct; 2(19):2513-2521. PubMed ID: 30282643
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
27. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
Larsson CA; Cote G; Quintás-Cardama A
Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
[TBL] [Abstract][Full Text] [Related]
28. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
Minetto P; Guolo F; Clavio M; De Astis E; Colombo N; Grasso R; Fugazza G; Sessarego M; Lemoli RM; Gobbi M; Miglino M
Leuk Res; 2015 Aug; 39(8):866-73. PubMed ID: 26012361
[TBL] [Abstract][Full Text] [Related]
29. Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.
Hasserjian RP; Buckstein R; Patnaik MM
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():328-350. PubMed ID: 34010050
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
32. Current status and trends in the diagnostics of AML and MDS.
Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
[TBL] [Abstract][Full Text] [Related]
33. Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
Ball S; Komrokji RS; Sallman DA
Leuk Lymphoma; 2022 Jun; 63(6):1281-1291. PubMed ID: 34933652
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia.
Klimek VM
Curr Opin Hematol; 2013 Mar; 20(2):137-43. PubMed ID: 23343830
[TBL] [Abstract][Full Text] [Related]
35. Risk stratifying MDS in the time of precision medicine.
Cazzola M
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
[TBL] [Abstract][Full Text] [Related]
36. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
37. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
38. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes.
Yao K; Zhou E; Schaafsma E; Zhang B; Cheng C
Cancer Med; 2023 Mar; 12(5):5590-5602. PubMed ID: 36394080
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
Sieglová Z; Zilovcová S; Cermák J; Ríhová H; Brezinová D; Dvoráková R; Marková M; Maaloufová J; Sajdová J; Brezinová J; Zemanová Z; Michalová K
Leuk Res; 2004 Oct; 28(10):1013-21. PubMed ID: 15289012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
